user

Altamira Therapeutics

Pharmaceutical Manufacturing

View the employees at

Altamira Therapeutics
  • image
    Arnaud BIERMANN, MSc, BSc Head of Regulatory Affairs (MedTech) | Senior Regulatory Affairs Manager (Biotech/Pharma) | Lean Manager (Operational Excellence)
    • Basel, Basel, Switzerland
    • Rising Star
    View Details
  • image
    samuel wickline Professor of Medicine, Biomedical Engineering, Cellular Physiology at University of South Florida
    • Tampa, Florida, United States
    • Top 1%
    View Details
  • image
    Heiko Walzinger Marketing & Key Account Manager at Altamira Medica AG
    • Basel Metropolitan Area
    • Rising Star
    View Details
  • image
    Maria Grunwald Business Development Executive, Advisor, fractional CXO in the life sciences industry
    • Cambridge
    • Rising Star
    View Details
  • image
    Arnaud BIERMANN, MSc, BSc Senior Regulatory Affairs Manager (Biotech/Pharma) | Head of Regulatory Affairs (MedTech) | PRRC | CH-REP | Swiss Importer | Lean Manager (Operational Excellence)
    • Top 5%
    View Details

Overview

Altamira Therapeutics (former Auris Medical) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: • the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003, under the name Auris Medical, and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”